These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9171622)

  • 21. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty.
    McGregor M; Brophy JM
    Can J Cardiol; 1999 Feb; 15(2):201-7. PubMed ID: 10079780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 25. Current coronary interventional practice.
    Hasdai D
    Cardiologia; 1998 Feb; 43(2):129-33. PubMed ID: 9557368
    [No Abstract]   [Full Text] [Related]  

  • 26. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 27. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
    Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
    Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interinstitutional variation in the use of abciximab for percutaneous coronary intervention.
    Westerhout CM; Saunders LD; Kaul P; Armstrong PW; Knudtson ML; Ghali WA
    Can J Cardiol; 2004 Mar; 20(4):405-10. PubMed ID: 15057316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 31. [The role of abciximab in the prevention of the acute thrombotic complications of coronary angioplasty].
    Mesquita A; Baptista J; Almeida M; Ferreira J; Machado F; Palos L; Silva A; Seabra-Gomes R
    Rev Port Cardiol; 1997 Dec; 16(12):1031-5. PubMed ID: 9522626
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
    Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation as a therapeutic target: a unique role for abciximab.
    Kereiakes DJ
    Am Heart J; 2003 Oct; 146(4 Suppl):S1-4. PubMed ID: 14564299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
    Kereiakes DJ; Broderick TM; Abbottsmith C; Shimshak TM
    J Invasive Cardiol; 2000 Feb; 12(2):95-8. PubMed ID: 10731271
    [No Abstract]   [Full Text] [Related]  

  • 36. A new therapeutic monoclonal antibody.
    Freeman PR
    J Am Pharm Assoc (Wash); 1996 Feb; NS36(2):90-1. PubMed ID: 8742006
    [No Abstract]   [Full Text] [Related]  

  • 37. Day-case transfer for percutaneous coronary intervention with adjunctive abciximab in acute coronary syndromes.
    Blackman DJ; Clarke NR; Orr WP; Wilkinson E; Beswick A; Coppock D; Sprigings DC; Banning AP
    Heart; 2002 Apr; 87(4):375-6. PubMed ID: 11907016
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 39. [Medical progress exemplified by improvements in the safety coronary angioplasty].
    Metzger JP
    Bull Acad Natl Med; 2012 Oct; 196(7):1361-7; discussion 1367-8. PubMed ID: 23815020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Murmurs from the heart (or why the stethoscope is not an economic tool).
    Aristides M; Gliksman M
    Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.